Our current pipeline is represented in the diagram below.
The lead asset, CLK CTX-712, is in phase I of the First in Human study.
※AML……Acute myeloid leukemia
※MDS……Myelodysplastic syndrome
※Chordia grants global rights of the CTX-177 to Ono Pharmaceuticals in Dec. 2020
